$3.70 Million in Sales Expected for Bicycle Therapeutics plc (NASDAQ:BCYC) This Quarter

Equities analysts expect Bicycle Therapeutics plc (NASDAQ:BCYCGet Rating) to report $3.70 million in sales for the current quarter, according to Zacks. Eight analysts have issued estimates for Bicycle Therapeutics’ earnings. The lowest sales estimate is $2.00 million and the highest is $4.18 million. Bicycle Therapeutics reported sales of $1.79 million during the same quarter last year, which would suggest a positive year over year growth rate of 106.7%. The company is expected to report its next earnings report on Monday, January 1st.

According to Zacks, analysts expect that Bicycle Therapeutics will report full-year sales of $15.83 million for the current year, with estimates ranging from $14.00 million to $17.55 million. For the next fiscal year, analysts forecast that the business will report sales of $18.34 million, with estimates ranging from $14.70 million to $25.00 million. Zacks Investment Research’s sales averages are a mean average based on a survey of analysts that cover Bicycle Therapeutics.

Bicycle Therapeutics (NASDAQ:BCYCGet Rating) last issued its quarterly earnings results on Thursday, May 5th. The company reported ($0.93) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.68) by ($0.25). Bicycle Therapeutics had a negative net margin of 568.71% and a negative return on equity of 31.61%.

Several research analysts have recently weighed in on the company. TheStreet lowered Bicycle Therapeutics from a “c-” rating to a “d+” rating in a research report on Thursday, April 21st. JMP Securities decreased their price objective on Bicycle Therapeutics from $85.00 to $70.00 and set a “market outperform” rating for the company in a report on Thursday, March 3rd. Needham & Company LLC decreased their price objective on Bicycle Therapeutics from $85.00 to $75.00 and set a “buy” rating for the company in a report on Tuesday, April 12th. Zacks Investment Research upgraded Bicycle Therapeutics from a “sell” rating to a “hold” rating in a research note on Monday, May 9th. Finally, Morgan Stanley initiated coverage on Bicycle Therapeutics in a research report on Monday, February 14th. They set an “equal weight” rating and a $60.00 target price on the stock. Three analysts have rated the stock with a hold rating and nine have assigned a buy rating to the company. According to MarketBeat, Bicycle Therapeutics has a consensus rating of “Buy” and a consensus target price of $65.08.

Shares of BCYC opened at $17.02 on Friday. The company has a market capitalization of $504.57 million, a PE ratio of -5.89 and a beta of 0.55. Bicycle Therapeutics has a 12 month low of $16.08 and a 12 month high of $62.08. The stock’s 50-day moving average price is $30.62 and its two-hundred day moving average price is $44.57. The company has a current ratio of 12.14, a quick ratio of 12.14 and a debt-to-equity ratio of 0.09.

Large investors have recently bought and sold shares of the stock. Citigroup Inc. raised its holdings in shares of Bicycle Therapeutics by 424.2% during the fourth quarter. Citigroup Inc. now owns 802 shares of the company’s stock worth $49,000 after purchasing an additional 649 shares during the last quarter. Prospera Financial Services Inc acquired a new stake in shares of Bicycle Therapeutics in the first quarter valued at about $88,000. Bank of America Corp DE grew its position in shares of Bicycle Therapeutics by 17.1% in the fourth quarter. Bank of America Corp DE now owns 2,524 shares of the company’s stock valued at $153,000 after purchasing an additional 368 shares during the period. JPMorgan Chase & Co. lifted its stake in shares of Bicycle Therapeutics by 107.2% in the fourth quarter. JPMorgan Chase & Co. now owns 2,828 shares of the company’s stock worth $172,000 after buying an additional 1,463 shares in the last quarter. Finally, Northern Trust Corp purchased a new position in shares of Bicycle Therapeutics in the fourth quarter worth about $177,000. 71.99% of the stock is owned by institutional investors.

Bicycle Therapeutics Company Profile (Get Rating)

Bicycle Therapeutics plc, a clinical-stage biopharmaceutical company, develops a class of medicines for diseases that are underserved by existing therapeutics. Its lead product candidate is BT1718, a bicycle toxin conjugate (BTC), which is in Phase I/IIa clinical trials targeting tumors that express Membrane Type 1 matrix metalloprotease.

Further Reading

Get a free copy of the Zacks research report on Bicycle Therapeutics (BCYC)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Earnings History and Estimates for Bicycle Therapeutics (NASDAQ:BCYC)

Receive News & Ratings for Bicycle Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Bicycle Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.